DCBO TOR Week ended 24 Jul 2026

Weekly Investor Report

Docebo Inc. · Technology · Software - Application

Open interactive chart View report data
Latest close 27.37 CAD
-4.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 6.6% above the Trend Line and sits at 29.1% of its 52-week range. The latest completed week returned -4.2%, after a 11.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.

Setup score 36 out of 100
Latest Close 27.37 CAD 24 Jul 2026
1W Return -4.2% latest completed week
4W Return 11.2% short-term follow-through
12W Return -2.2% quarterly tape
Trend Breadth 1.9% 1 of 52 weeks active
Volume Ratio 1.1x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
  • The share remains more than 20% below its 52-week high.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.2% Latest completed week; four-week move 11.2%. Indicator stack 1/86 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 51/100 33 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 6.6% above the Trend Line and sits at 29.1% of its 52-week range. The latest completed week returned -4.2%, after a 11.2% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.1x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2512-week average 0.14

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.25Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 11.2% over four weeks, -2.2% over 12 weeks, and -36.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.2%
4W11.2%
12W-2.2%
26W7.4%
52W-36.5%
Active trend streak0 weeks
Active weeks in one year1
Trend breadth1.9%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.26Latest activity-pressure read.
Pressure change168.0%Four-week change in activity pressure.
Leadership-19.79Latest relative-leadership reading.
RS change36.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 85% Model confidence 81%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength15/100Blend of value, momentum, and quality. Underlying universe rank 86; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality71/100Profitability and accounting quality. Underlying universe rank 30; rank 1 is best.
Momentum4/100Medium-term price momentum. Underlying universe rank 97; rank 1 is best.
Growth87/100Revenue and earnings growth. Underlying universe rank 14; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
20.2x
Price divided by trailing earnings.
Price / sales
2.8x
Market value relative to trailing revenue.
EV / EBITDA
28.4x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
6.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
79.8%
Gross profit retained from each unit of revenue.
Operating margin
9.0%
Operating profit retained from revenue.
Free-cash-flow margin
17.6%
Free cash flow generated from revenue.
Return on invested capital
84.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
11.9%
Latest one-year revenue growth.
EPS growth
47.7%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-2.9%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
14.4%
Net share repurchases relative to market value.
Shareholder yield
14.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 33 relevant articles.

5 positive · 27 neutral · 1 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-40.0%Distance below the 52-week high.
13-week volatility7.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+12.7%Week of 17 Apr.
Worst week-18.3%Week of 15 May.
Latest week-4.2%Week of 24 Jul.

Shape of recent returns

Strong gains8
Modest gains8
Flat weeks0
Modest losses5
Sharp losses5
Recent vol7.1%13-week weekly-return volatility.
Base vol6.2%52-week weekly-return volatility.
Up/down split23/29Count of positive and negative weeks in the 52-week window.
Average skew4.5% / -4.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape30/100

Trend, activity pressure, participation, and risk combine to a 30/100 tape read.

 Indicator analysis34/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.25; No reversal markers Factors28/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 2; Small Cap Core rank 67 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Sentiment51/100

Weighted news tone is neutral across 33 relevant articles.

DCBO|Docebo Inc|Price:21.950|Chg%:+0.960 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202627.37 CAD-4.2%25.67 CAD47.36 CAD1.26-19.79402.5KOff
17 Jul 202628.56 CAD8.0%25.76 CAD47.50 CAD1.02-17.36361.2KOff
10 Jul 202626.44 CAD2.5%25.82 CAD47.65 CAD0.69-24.63142.5KOff
3 Jul 202625.80 CAD4.8%25.95 CAD47.80 CAD0.58-27.31180.5KOff
26 Jun 202624.62 CAD0.7%26.09 CAD47.96 CAD0.47-31.07247.8KOff
19 Jun 202624.45 CAD-3.4%26.25 CAD48.13 CAD0.68-32.4625.5KOff
12 Jun 202625.32 CAD4.9%26.42 CAD48.29 CAD0.72-30.8449.2KOff
5 Jun 202624.13 CAD-2.6%26.61 CAD48.45 CAD0.80-33.8459.7KOff
29 May 202624.77 CAD2.7%26.91 CAD48.60 CAD1.04-33.621.2MOff
22 May 202624.11 CAD1.5%27.25 CAD48.74 CAD1.02-35.66293.1KOff
15 May 202623.75 CAD-18.3%27.76 CAD48.86 CAD1.08-36.21744.3KOff
8 May 202629.06 CAD3.8%28.20 CAD49.00 CAD0.86-23.49552.2KOff
1 May 202628.00 CAD12.2%28.48 CAD49.08 CAD0.31-26.64436.4KOff
24 Apr 202624.96 CAD8.8%28.83 CAD49.21 CAD-0.06-35.64621.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.